Research programme: Alzheimer's disease therapy - Myriad Pharmaceuticals

Drug Profile

Research programme: Alzheimer's disease therapy - Myriad Pharmaceuticals

Alternative Names: MPI 127585; MPI 423948; MPI-442690; MPYS 315

Latest Information Update: 25 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Myriad Pharmaceuticals
  • Class
  • Mechanism of Action Amyloid precursor protein secretase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 25 Sep 2009 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 17 Aug 2007 Preclinical development is ongoing
  • 17 Jun 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top